↓ Skip to main content

Cochrane Database of Systematic Reviews

Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review

Overview of attention for article published in Cochrane database of systematic reviews, September 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (82nd percentile)
  • Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Citations

dimensions_citation
88 Dimensions

Readers on

mendeley
150 Mendeley
Title
Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review
Published in
Cochrane database of systematic reviews, September 2012
DOI 10.1002/14651858.cd001901.pub2
Pubmed ID
Authors

Gashirai K Mbizvo, Pete Dixon, Jane L Hutton, Anthony G Marson

Abstract

Epilepsy is an important neurological condition and drug resistance in epilepsy is particularly common in individuals with focal seizures. In this review, we summarise the current evidence regarding a new antiepileptic drug, levetiracetam, when used as add-on treatment for controlling drug-resistant focal epilepsy. This is an update to a Cochrane Review that was originally published in 2001.

Mendeley readers

The data shown below were compiled from readership statistics for 150 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 1%
Italy 2 1%
United Kingdom 1 <1%
Canada 1 <1%
Unknown 144 96%

Demographic breakdown

Readers by professional status Count As %
Student > Master 36 24%
Researcher 20 13%
Student > Postgraduate 13 9%
Student > Ph. D. Student 12 8%
Other 11 7%
Other 30 20%
Unknown 28 19%
Readers by discipline Count As %
Medicine and Dentistry 60 40%
Nursing and Health Professions 12 8%
Psychology 12 8%
Neuroscience 8 5%
Pharmacology, Toxicology and Pharmaceutical Science 6 4%
Other 16 11%
Unknown 36 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 December 2020.
All research outputs
#2,749,112
of 15,827,677 outputs
Outputs from Cochrane database of systematic reviews
#5,502
of 11,293 outputs
Outputs of similar age
#25,338
of 154,789 outputs
Outputs of similar age from Cochrane database of systematic reviews
#36
of 87 outputs
Altmetric has tracked 15,827,677 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,293 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 23.5. This one has gotten more attention than average, scoring higher than 50% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 154,789 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 87 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.